The Impact of a New Interleukin-2-Based Immunotherapy Candidate on Urothelial Cells to Support Use for Intravesical Drug Delivery
(1) Background: The intravesical instillation of interleukin-2 (IL-2) has been shown to be very well tolerated and promising in patients with bladder malignancies. This study aims to confirm the use of a new IL-2 containing immunotherapy candidate as safe for intravesical application. IL-2, produced...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-10-01
|
| Series: | Life |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-1729/10/10/231 |
| _version_ | 1797551771800829952 |
|---|---|
| author | Lisa Schmitz Belinda Berdien Edith Huland Petra Dase Karin Beutel Margit Fisch Oliver Engel |
| author_facet | Lisa Schmitz Belinda Berdien Edith Huland Petra Dase Karin Beutel Margit Fisch Oliver Engel |
| author_sort | Lisa Schmitz |
| collection | DOAJ |
| description | (1) Background: The intravesical instillation of interleukin-2 (IL-2) has been shown to be very well tolerated and promising in patients with bladder malignancies. This study aims to confirm the use of a new IL-2 containing immunotherapy candidate as safe for intravesical application. IL-2, produced in mammalian cells, is glycosylated, because of its unique solubility and stability optimized for intravesical use. (2) Materials and Methods: Urothelial cells and fibroblasts were generated out of porcine bladder and cultured until they reached second passage. Afterwards, they were cultivated in renal epithelial medium (REM) and Dulbecco’s modified Eagles medium (DMEM) with the IL-2 candidate (IMS-Research) and three more types of human interleukin-2 immunotherapy products (IMS-Pure, Natural IL-2, Aldesleukin) in four different concentrations (100, 250, 500, 1000 IU/mL). Cell proliferation was analyzed by water soluble tetrazolium (WST) proliferation assay after 0, 3, and 6 days for single cell culture and co-culture. (3) Results: Proliferation assays showed that all IL-2 products induced very similar cultivation results and none of the IL-2 variants had a negative impact on the proliferation of urothelial cells and fibroblast in either concentration. (4) Conclusion: Human recombinant glycosylated IL-2 as well as human non-glycosylated IL-2 have no negative influence on the tissue cell proliferation of porcine urothelial cells and fibroblasts in vitro and represent a promising and innovative potential intravesical therapy candidate for patients in high need. |
| first_indexed | 2024-03-10T15:50:43Z |
| format | Article |
| id | doaj.art-6bf7f1afe5984a5baaf8dca63b636ac3 |
| institution | Directory Open Access Journal |
| issn | 2075-1729 |
| language | English |
| last_indexed | 2024-03-10T15:50:43Z |
| publishDate | 2020-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Life |
| spelling | doaj.art-6bf7f1afe5984a5baaf8dca63b636ac32023-11-20T16:05:38ZengMDPI AGLife2075-17292020-10-01101023110.3390/life10100231The Impact of a New Interleukin-2-Based Immunotherapy Candidate on Urothelial Cells to Support Use for Intravesical Drug DeliveryLisa Schmitz0Belinda Berdien1Edith Huland2Petra Dase3Karin Beutel4Margit Fisch5Oliver Engel6Department of Urology, University Medical Center Hamburg-Eppendorf (UKE), 20251 Hamburg, GermanyImmunservice GmbH, 20251 Hamburg, GermanyImmunservice GmbH, 20251 Hamburg, GermanyDepartment of Urology, University Medical Center Hamburg-Eppendorf (UKE), 20251 Hamburg, GermanyDepartment of Urology, University Medical Center Hamburg-Eppendorf (UKE), 20251 Hamburg, GermanyDepartment of Urology, University Medical Center Hamburg-Eppendorf (UKE), 20251 Hamburg, GermanyDepartment of Urology, University Medical Center Hamburg-Eppendorf (UKE), 20251 Hamburg, Germany(1) Background: The intravesical instillation of interleukin-2 (IL-2) has been shown to be very well tolerated and promising in patients with bladder malignancies. This study aims to confirm the use of a new IL-2 containing immunotherapy candidate as safe for intravesical application. IL-2, produced in mammalian cells, is glycosylated, because of its unique solubility and stability optimized for intravesical use. (2) Materials and Methods: Urothelial cells and fibroblasts were generated out of porcine bladder and cultured until they reached second passage. Afterwards, they were cultivated in renal epithelial medium (REM) and Dulbecco’s modified Eagles medium (DMEM) with the IL-2 candidate (IMS-Research) and three more types of human interleukin-2 immunotherapy products (IMS-Pure, Natural IL-2, Aldesleukin) in four different concentrations (100, 250, 500, 1000 IU/mL). Cell proliferation was analyzed by water soluble tetrazolium (WST) proliferation assay after 0, 3, and 6 days for single cell culture and co-culture. (3) Results: Proliferation assays showed that all IL-2 products induced very similar cultivation results and none of the IL-2 variants had a negative impact on the proliferation of urothelial cells and fibroblast in either concentration. (4) Conclusion: Human recombinant glycosylated IL-2 as well as human non-glycosylated IL-2 have no negative influence on the tissue cell proliferation of porcine urothelial cells and fibroblasts in vitro and represent a promising and innovative potential intravesical therapy candidate for patients in high need.https://www.mdpi.com/2075-1729/10/10/231interleukin-2urothelial cellsintravesicalimmunotherapybladder cancer |
| spellingShingle | Lisa Schmitz Belinda Berdien Edith Huland Petra Dase Karin Beutel Margit Fisch Oliver Engel The Impact of a New Interleukin-2-Based Immunotherapy Candidate on Urothelial Cells to Support Use for Intravesical Drug Delivery Life interleukin-2 urothelial cells intravesical immunotherapy bladder cancer |
| title | The Impact of a New Interleukin-2-Based Immunotherapy Candidate on Urothelial Cells to Support Use for Intravesical Drug Delivery |
| title_full | The Impact of a New Interleukin-2-Based Immunotherapy Candidate on Urothelial Cells to Support Use for Intravesical Drug Delivery |
| title_fullStr | The Impact of a New Interleukin-2-Based Immunotherapy Candidate on Urothelial Cells to Support Use for Intravesical Drug Delivery |
| title_full_unstemmed | The Impact of a New Interleukin-2-Based Immunotherapy Candidate on Urothelial Cells to Support Use for Intravesical Drug Delivery |
| title_short | The Impact of a New Interleukin-2-Based Immunotherapy Candidate on Urothelial Cells to Support Use for Intravesical Drug Delivery |
| title_sort | impact of a new interleukin 2 based immunotherapy candidate on urothelial cells to support use for intravesical drug delivery |
| topic | interleukin-2 urothelial cells intravesical immunotherapy bladder cancer |
| url | https://www.mdpi.com/2075-1729/10/10/231 |
| work_keys_str_mv | AT lisaschmitz theimpactofanewinterleukin2basedimmunotherapycandidateonurothelialcellstosupportuseforintravesicaldrugdelivery AT belindaberdien theimpactofanewinterleukin2basedimmunotherapycandidateonurothelialcellstosupportuseforintravesicaldrugdelivery AT edithhuland theimpactofanewinterleukin2basedimmunotherapycandidateonurothelialcellstosupportuseforintravesicaldrugdelivery AT petradase theimpactofanewinterleukin2basedimmunotherapycandidateonurothelialcellstosupportuseforintravesicaldrugdelivery AT karinbeutel theimpactofanewinterleukin2basedimmunotherapycandidateonurothelialcellstosupportuseforintravesicaldrugdelivery AT margitfisch theimpactofanewinterleukin2basedimmunotherapycandidateonurothelialcellstosupportuseforintravesicaldrugdelivery AT oliverengel theimpactofanewinterleukin2basedimmunotherapycandidateonurothelialcellstosupportuseforintravesicaldrugdelivery AT lisaschmitz impactofanewinterleukin2basedimmunotherapycandidateonurothelialcellstosupportuseforintravesicaldrugdelivery AT belindaberdien impactofanewinterleukin2basedimmunotherapycandidateonurothelialcellstosupportuseforintravesicaldrugdelivery AT edithhuland impactofanewinterleukin2basedimmunotherapycandidateonurothelialcellstosupportuseforintravesicaldrugdelivery AT petradase impactofanewinterleukin2basedimmunotherapycandidateonurothelialcellstosupportuseforintravesicaldrugdelivery AT karinbeutel impactofanewinterleukin2basedimmunotherapycandidateonurothelialcellstosupportuseforintravesicaldrugdelivery AT margitfisch impactofanewinterleukin2basedimmunotherapycandidateonurothelialcellstosupportuseforintravesicaldrugdelivery AT oliverengel impactofanewinterleukin2basedimmunotherapycandidateonurothelialcellstosupportuseforintravesicaldrugdelivery |